Liliana Pitu, NP
Nurse Practitioner · Winston Salem, NCNPI 1942779475
Payments from drug & device makers
Across 304 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$604
- Abbott$478
- Boehringer Ingelheim$401
- Medtronic$394
- Insulet Corporation$382
- plus $1K from 16 others
What the payments were for
- Food & beverage$5,072100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 106 | $1,380 |
| Lilly USA, LLC | 35 | $604 |
| Abbott | 40 | $478 |
| Boehringer Ingelheim | 27 | $401 |
| Medtronic | 9 | $394 |
| Insulet Corporation | 14 | $382 |
| Sanofi-aventis U.S. LLC | 12 | $348 |
| Mannkind Corporation | 12 | $202 |
| Dexcom, Inc. | 11 | $183 |
| Tandem Diabetes Care, Inc. | 10 | $128 |
| AbbVie | 6 | $112 |
| Cequr Corporation | 2 | $97 |
| Xeris Pharmaceuticals, Inc. | 5 | $91 |
| BETA Bionics, Inc. | 2 | $55 |
| Sequel Med Tech, LLC | 3 | $53 |
| Bayer | 2 | $38 |
| AstraZeneca | 2 | $33 |
| Amphastar Pharmaceuticals, Inc. | 2 | $33 |
| Corcept Therapeutics | 1 | $25 |
| Amgen | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Clarus Therapeutics Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 630G$134
- Omnipod$134
- SOLIQUA 100/33$125
- RYBELSUS$120
- FreeStyle Libre Pro$113
- MOUNJARO$108
How this compares
$5,084 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 455 | $544,684 |
| JardianceEmpagliflozin | 371 | $322,699 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 227 | $294,964 |
| MounjaroTirzepatide | 177 | $203,877 |
| FarxigaDapagliflozin Propanediol | 196 | $172,994 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 98 | $111,735 |
| RybelsusSemaglutide | 83 | $110,752 |
| Tresiba Flextouch U-200Insulin Degludec | 112 | $106,128 |
| Tresiba Flextouch U-100Insulin Degludec | 162 | $96,131 |
| TrulicityDulaglutide | 61 | $78,906 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 79 | $65,258 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 31 | $54,311 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 43 | $46,873 |
| Humalog Kwikpen U-100Insulin Lispro | 146 | $39,021 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 227 | $37,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Fiasp, Novolog | $1,380 | $696,358579 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $401 | $356,599412 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $604 | $316,316304 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $348 | $299,650252 claims |
| AstraZenecaFarxiga | $33 | $172,994196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Winston Salem
- Olivia OgburnWinston Salem$70K
- Amy MitchellWinston Salem$33K
- Mary SandsWinston Salem$32K
- Ladonna CookWinston Salem$23K
- Gillian WinterWinston Salem$18K
- Christine ZdebWinston Salem$15K
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.